![]() ![]() Known or suspected active drug or alcohol abuse. ![]() Known or active human immunodeficiency virus (HIV) or hepatitis B or C virus unless cured.Evidence of renal obstruction based on Tc-99m DTPA or TER for MAG3 renal scintigraphy or renal ultrasound.Uncontrolled diabetes mellitus as defined by a hemoglobin A1C >10.0.Uncontrolled congestive heart failure (NYHA II, III, IV).Experimental cancer treatments or other investigational therapies within 6 weeks or five half-lives of the investigational medication prior to Day 1.Known brain metastases, unless these metastases have been treated and/or stable for 6 months prior to enrollment.Indication for surgical lesion removal with curative potential.Female subjects who are pregnant or lactating.History of myelodysplastic syndrome (MDS).Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28 days) and Sandostatin® (within 1 day) prior to administration of study drug.Known hypersensitivity to somatostatin analogues, AA infusion, or 212Pb-DOTAMTATE.Prior regional hepatic radionuclide therapy within 4 months prior to enrollment or prior nonradioactive regional hepatic therapy within 6 months prior to enrollment.Prior whole-body radiotherapy or PRRT using 177Lu/90Y/111In-DOTATATE/ DOTATOC or TAT.Be willing to practice the following medically acceptable methods of birth control (both women of childbearing potential (WOCBP) and men who have partners of childbearing potential) from the Screening Visit through 3 months after the final administration 212Pb-DOTAMTATE.Serum albumin ≥3.0 g/L if lower than 3.0 g/L requires normal range prothrombin time (PT) and international normalized ratio (INR), and.Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤3 X upper limit of normal (ULN).Absolute neutrophil count (ANC) ≥1000/mm3. ![]() Sufficient bone marrow capacity and organ function in the recent blood tests within 3 weeks prior to Day 1, as defined by: Life expectancy of at least 12 weeks in the opinion of the investigator at the time of screening. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |